Yang K, Islas N, Jewell S, Wu D, Jha A, Radens C
Nucleic Acids Res. 2024; 53(3).
PMID: 39727154
PMC: 11797022.
DOI: 10.1093/nar/gkae1260.
Yang K, Islas N, Jewell S, Jha A, Radens C, Pleiss J
bioRxiv. 2024; .
PMID: 39386495
PMC: 11463589.
DOI: 10.1101/2024.09.20.614162.
Shil R, Mohammed N, Dimitroff C
Front Immunol. 2024; 15:1469794.
PMID: 39386209
PMC: 11461229.
DOI: 10.3389/fimmu.2024.1469794.
Beyer S, Wehrmann M, Meister S, Trillsch F, Ganster F, Schmoeckel E
Int J Mol Sci. 2024; 25(13).
PMID: 39000016
PMC: 11241125.
DOI: 10.3390/ijms25136907.
Suszczyk D, Skiba W, Pawlowska-Lachut A, Dymanowska-Dyjak I, Wlodarczyk K, Paduch R
Int J Mol Sci. 2024; 25(11).
PMID: 38892453
PMC: 11172867.
DOI: 10.3390/ijms25116266.
The role of galectins in mediating the adhesion of circulating cells to vascular endothelium.
Souchak J, Mohammed N, Lau L, Dimitroff C
Front Immunol. 2024; 15:1395714.
PMID: 38840921
PMC: 11150550.
DOI: 10.3389/fimmu.2024.1395714.
Killer instincts: natural killer cells as multifactorial cancer immunotherapy.
Nersesian S, Carter E, Lee S, Westhaver L, Boudreau J
Front Immunol. 2023; 14:1269614.
PMID: 38090565
PMC: 10715270.
DOI: 10.3389/fimmu.2023.1269614.
Galectin-9 Expression is Correlated to Cervical Squamous Cell Carcinoma Progression and Overall Survival.
Mendieta-Carmona V, Delgado-Lopez G, Reyes-Leyva J, Gutierrez-Quiroz C, Vazquez-Zamora V, Picazo-Mendoza D
Onco Targets Ther. 2023; 16:891-904.
PMID: 37927328
PMC: 10625380.
DOI: 10.2147/OTT.S433710.
Evaluation of the Relationship Between miRNA-22-3p and Gal-9 Levels in Glioblastoma.
Barut Z, Akdeniz F
In Vivo. 2023; 37(6):2577-2584.
PMID: 37905655
PMC: 10621420.
DOI: 10.21873/invivo.13365.
Tumor-derived interleukin-1 receptor antagonist exhibits immunosuppressive functions and promotes pancreatic cancer.
Fan Y, Fong Y, Kuo C, Li C, Chen W, Lin J
Cell Biosci. 2023; 13(1):147.
PMID: 37563620
PMC: 10416534.
DOI: 10.1186/s13578-023-01090-8.
Galectins dysregulation: A way for cancer cells to invade and pervade.
Abdelfattah M, Helwa R
Oncol Res. 2023; 30(3):129-135.
PMID: 37305017
PMC: 10208010.
DOI: 10.32604/or.2022.026838.
Galectin-9 expression on tumour-associated immune cells is associated with favourable clinicopathological features and better outcomes in oral squamous cell carcinoma.
Peksa R, Kunc M, Piatek M, Radecka B, Jereczek-Fossa B, Starzynska A
Contemp Oncol (Pozn). 2023; 27(1):22-27.
PMID: 37266336
PMC: 10230243.
DOI: 10.5114/wo.2023.127142.
CD71 erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors.
Bozorgmehr N, Okoye I, Mashhouri S, Lu J, Koleva P, Walker J
J Immunother Cancer. 2023; 11(5).
PMID: 37236637
PMC: 10230995.
DOI: 10.1136/jitc-2022-006595.
Galectin-9 in Gastroenterological Cancer.
Morishita A, Oura K, Tadokoro T, Shi T, Fujita K, Tani J
Int J Mol Sci. 2023; 24(7).
PMID: 37047155
PMC: 10094448.
DOI: 10.3390/ijms24076174.
T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review.
Cazzato G, Cascardi E, Colagrande A, Lettini T, Filosa A, Arezzo F
Cancers (Basel). 2023; 15(6).
PMID: 36980583
PMC: 10046653.
DOI: 10.3390/cancers15061697.
Inhibition of galectins in cancer: Biological challenges for their clinical application.
Laderach D, Compagno D
Front Immunol. 2023; 13:1104625.
PMID: 36703969
PMC: 9872792.
DOI: 10.3389/fimmu.2022.1104625.
Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance.
Gerace D, Zhou Q, Kenty J, Veres A, Sintov E, Wang X
Cell Rep Med. 2023; 4(1):100879.
PMID: 36599351
PMC: 9873825.
DOI: 10.1016/j.xcrm.2022.100879.
Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy.
Lau L, Mohammed N, Dimitroff C
Int J Mol Sci. 2022; 23(24).
PMID: 36555198
PMC: 9778980.
DOI: 10.3390/ijms232415554.
Multiregional single-cell dissection of tumor and immune cells reveals stable lock-and-key features in liver cancer.
Ma L, Heinrich S, Wang L, Keggenhoff F, Khatib S, Forgues M
Nat Commun. 2022; 13(1):7533.
PMID: 36476645
PMC: 9729309.
DOI: 10.1038/s41467-022-35291-5.
Serum Levels of Galectin-9 are Increased in Cervical Cancer Patients and are Higher in Advanced Clinical Stages.
Reyes-Vallejo T, Conde-Rodriguez I, Serna-Villalobos J, Ramirez-Diaz I, Perez-Villalobos G, Delgado-Lopez G
Onco Targets Ther. 2022; 15:1211-1220.
PMID: 36246733
PMC: 9556277.
DOI: 10.2147/OTT.S378933.